- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
NPS Pharmaceuticals Inc
+ Add to WatchlistNPSP:US
15.2500 USD 0.3000 2.01%As of 20:10:00 ET on 05/23/2013.
Snapshot for NPS Pharmaceuticals Inc (NPSP)
| Open: | 14.5900 | Day's Range: | 14.2500 - 15.4150 | Volume: | 3,054,075 |
|---|---|---|---|---|---|
| Previous Close: | 15.2500 | 52wk Range: | 6.6200 - 16.3700 | 1-Yr Rtn: | +94.27% |
Key Statistics for NPSP
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.1900 |
| Est. EPS (USD) (12/2013) | -0.1960 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 1,530.08 |
| Shares Outstanding (M) | 100.33 |
| 30 Day Average Volume | 1,987,411 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | 9.9948 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/01/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for NPSP
Company Profile & Key Executives for NPSP
NPS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of treatment options for patients with rare gastrointestinal and endocrine disorders and serious unmet medical needs.
| Francois NaderPresident/CEO | Luke Matthew BesharExec VP/CFO |
| Roger J GarceauExec VP/Chief Medical Officer | Eric PauwelsSenior VP/Chief Commercial Ofcr |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
NPSP News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page